Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 142, Issue 12, Pages 2515-2522Publisher
SPRINGER
DOI: 10.1007/s00432-016-2215-3
Keywords
Endometrial lesions; Aspiration; Biopsy; Brush; Screening
Categories
Funding
- Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University, China [XJTU1AH2014-007]
- International Cooperation Project of Shaanxi Province [2013kw-30-04]
- National Natural Science Foundation of China [81472823]
- Fundamental Research Funds for Xi'an Jiaotong University [xjj2015093]
Ask authors/readers for more resources
Endometrial carcinoma is the most common gynecologic malignancy in both developed and some developing countries. Unlike cervical cancer, for which there is routine screening, only patients symptomatic for endometrial carcinoma typically seek medical help for its diagnosis and treatment. Dilatation and curettage (D&C) has been the standard procedure for evaluating suspicious endometrial lesions. The discomfort and injury caused by the D&C procedure, however, restrict its use as a screening method for early diagnosis of endometrial lesions. High-risk endometrial cancer patients would benefit from an effective and low-cost screening test. In recent years, several endometrial devices have been developed and proposed as screening tools. We have reviewed and evaluated the literature relating to the endometrial sampling devices in clinical use or clinical trials, with the goal of comparing devices and identifying the most appropriate ones for screening for endometrial lesions. Eligible literature was identified from systematic PubMed searches, and the relevant data were extracted. Comments, letters, unpublished data, conference proceedings, and case reports were excluded from our search. Seventy-four articles on endometrial sampling devices were obtained for this review. The main screening devices for endometrial carcinoma are aspiration devices (such as the Vabra aspirator), Pipelle, Tao Brush, and SAP-1 device. Among these devices, the Tao Brush is the most promising endometrial sampler for screening for endometrial lesions. However, its sampling insufficiency, cost, and unsuccessful insertion rate (20 % in nulliparous and 8 % in parous women) are problematic. A more accurate and low-cost endometrial sampler, with improved specimen sufficiency and higher sensitivity for endometrial lesions, needs tobe developed and clinically verified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available